AstraZeneca's Calquence Achieves 90.2% CMR in Transplant-Eligible MCL First-Line Phase 2 Trial
Deep Responses Observed in Transplant-Eligible Patient Cohort
The CARiBOU Phase 2 trial (NCT04626791), conducted by ACCRU, evaluated 41 previously untreated transplant-eligible mantle cell lymphoma (MCL) patients. Over six 21-day cycles, modified VR-CAP was alternated with rituximab and cytarabine, with AstraZeneca's Calquence (acalabrutinib) administered continuously as combination therapy. Calquence selectively inhibits Bruton tyrosine kinase (BTK), a key component of B-cell receptor signaling, thereby complementing the tumor reduction effect of chemoimmunotherapy. As a single-arm study without a control group, the results should be interpreted as a basis for subsequent comparative trials.
Clinical Significance of 90.2% CMR and MRD-Negative Outcomes
Among the 41 patients, 95% (39 patients) achieved objective response, and 90.2% (37 patients) achieved complete metabolic response (CMR). Of the 33 evaluable patients by clonoSEQ testing, 79% (26 patients) achieved measurable residual disease (MRD)-negative status at 10^-6 sensitivity, and 94% were MRD-negative at the 10^-5 threshold. The 18-month progression-free survival (PFS) was 79% (95% CI: 64–97%), and overall survival (OS) was 96% (95% CI: 88–100%). High CMR and deep MRD clearance support a strategy of individualized adjustment of transplantation and maintenance therapy, but longer follow-up and a larger cohort are needed to confirm long-term disease control.
Outpatient Treatment Efficiency and Hematologic Toxicity
CARiBOU reduced the burden of inpatient induction therapy by implementing an outpatient-based regimen with intermediate-dose cytarabine as part of an intensive combination therapy. However, 78% (32 patients) experienced Grade 3 or higher hematologic adverse events, 12 patients required platelet transfusions, and one case of Grade 3 bleeding and four cases of febrile neutropenia were reported. Serious adverse events occurred in 14% (6 patients), but no treatment-related deaths were reported. Therefore, the key to expanding prescribing lies not in the response rate itself, but in the real-world treatment efficiency, including infection and bleeding management, stem cell collection, and transplant transition rates.
Regulatory Status and Competitive Landscape
The FDA granted accelerated approval to Calquence for MCL in patients with prior therapy on October 31, 2017, and converted it to full approval for the monotherapy indication on January 16, 2025. On the same day, the FDA granted full approval for the combination of Calquence with bendamustine and rituximab in transplant-ineligible, previously untreated patients based on the Phase 3 ECHO trial. However, the transplant-eligible first-line patient population addressed by CARiBOU follows a separate Phase 2 strategy. Competitors include Janssen and AbbVie's Imbruvica (ibrutinib, BTK), BeiGene's Brukinsa (zanubrutinib, BTK), and rituximab-based high-dose cytarabine induction therapy with autotransplantation. The 2024 global MCL market is valued at USD 2.53 billion, and Calquence's total sales across all indications reached USD 3.129 billion. If evidence expands to include transplant-eligible patients, AstraZeneca's hematologic oncology franchise will be further strengthened.
The CARiBOU Phase 2 trial recorded a 90.2% CMR and 79% MRD-negative rate at the 10^-6 threshold in 41 transplant-eligible, previously untreated MCL patients, providing evidence to expand Calquence's first-line use beyond elderly and transplant-ineligible populations. In the short term, this will intensify clinical trial competition in the USD 2.53 billion 2024 global MCL market against Imbruvica, Brukinsa, and high-dose cytarabine with autotransplantation strategies. For researchers, it offers a foundation to validate MRD-based decisions to omit transplantation or choose maintenance therapy, but the 79% 18-month PFS and the single-arm design with 41 patients necessitate a randomized Phase 3 comparison. For the industry, outpatient administration is an operational advantage, but the 78% incidence of Grade 3 or higher hematologic adverse events and 12 platelet transfusions remain key risks that will influence commercial value and prescribing penetration.
Source: ClinicalTrials.gov (api_ct)